SynaptiQ: The Berlin Biotech Startup You Need to Know About This Month

In a converted warehouse on Markgrafenstraße in Berlin-Mitte, a team of 120 neuroscientists and engineers are quietly building what could become Europe's most significant breakthrough in neural interface technology. SynaptiQ, founded in 2021, announced its Series B funding round today—€47 million led by Salesforce Ventures and the European Innovation Council—marking a decisive moment for Berlin's biotech ambitions and a direct challenge to the Silicon Valley-dominated brain-computer interface sector.

The company's technology focuses on non-invasive neural signal decoding, positioning electrodes across the scalp rather than implanting devices directly into brain tissue. This approach eliminates the surgical risks that have plagued competitors like Neuralink, while maintaining sufficient signal fidelity for real-world medical applications. Early clinical trials conducted in partnership with the Charité Hospital have shown promising results in helping patients with severe motor paralysis regain communication ability.

What makes SynaptiQ's emergence significant goes beyond the technology itself. The company represents a maturing European alternative to American venture capital dominance in deep-tech sectors. Founders Dr. Katrin Weber and Dr. Marcus Hensel built the team primarily from Berlin's existing talent pool—recruiting researchers from the Max Planck Institute for Human Cognitive and Brain Sciences and engineers from the city's software engineering heritage in Kreuzberg and Friedrichshain.

The €47 million injection will fund expansion into their new 5,000-square-meter facility near the Ostkreuz rail junction, where they plan to scale manufacturing of their proprietary electrode arrays and accelerate their path toward regulatory approval in the EU. This represents a significant shift: rather than seeking FDA approval first like most European biotech firms, SynaptiQ is pursuing EMA clearance in parallel, betting that European regulatory frameworks will prove equally or more accessible.

The broader context matters here. Berlin's tech sector has largely remained synonymous with software startups and platform companies. But investment in deep-tech—biotech, quantum computing, advanced materials—has grown from 8% of the city's venture funding in 2019 to nearly 24% by 2025. SynaptiQ exemplifies this maturation, attracting institutional capital precisely because it combines scientific rigor with clear commercial pathways.

The announcement arrives as Berlin continues positioning itself as a serious contender in the biotechnology sector, competing with Munich and Basel for investment and talent. With the first commercial applications potentially available within 24 months, SynaptiQ's trajectory will reveal whether Berlin can sustain its momentum in high-stakes, capital-intensive innovation beyond software.

This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.